Halozyme Therapeutics (HALO) has risen sharply, recording gains of 15.56% in the past 4 weeks. However, the stock has corrected -2.29% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 14.38% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.13% and the 50-Day Moving Average is 11.04%. Halozyme Therapeutics (NASDAQ:HALO): stock turned positive on Friday. Though the stock opened at $10.15, the bulls momentum made the stock top out at $10.3 level for the day. The stock recorded a low of $10.01 and closed the trading day at $10.25, in the green by 0.89%. The total traded volume for the day was 663,805. The stock had closed at $10.16 in the previous days trading.
The company Insiders own 16.6% of Halozyme Therapeutics shares according to the proxy statements. Institutional Investors own 79.61% of Halozyme Therapeutics shares.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.